GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (GCAR1) for a patient with metastatic epithelioid hemangioendothelioma (EHE) (CLIC-YYC-GPNMB-02)

Summary

Scientists in Calgary have joined forces to develop a new type of medicine for patients with rare cancers. This cutting edge treatment will now be tested in a single patient here with an incurable disease who has no more treatment options.

Eligibility

Currently recruiting participants: No

Eligible ages: 0 to 100

Inclusion criteria:

This study is only for a pre-identified single patient.

Exclusion criteria:

This study is only for a pre-identified single patient.

Participate

Sorry, this study is not currently accepting new participants.
Browse other research studies.

Additional information

Contact information

n/a

Principal investigator:

Victor Anthony Lewis

Clinical trial:

Yes

REB-ID:

HREBA.CC-23-0010